Valion Bio (TIVC) Retained Earnings (2021 - 2025)
Valion Bio has reported Retained Earnings over the past 5 years, most recently at -$52.6 million for Q4 2025.
- For Q4 2025, Retained Earnings fell 20.8% year-over-year to -$52.6 million; the TTM value through Dec 2025 reached -$52.6 million, down 20.8%, while the annual FY2025 figure was -$52.6 million, 20.8% down from the prior year.
- Retained Earnings for Q4 2025 was -$52.6 million at Valion Bio, down from -$49.6 million in the prior quarter.
- Over five years, Retained Earnings peaked at -$19.5 million in Q4 2021 and troughed at -$52.6 million in Q4 2025.
- A 5-year average of -$36.6 million and a median of -$37.9 million in 2023 define the central range for Retained Earnings.
- Biggest five-year swings in Retained Earnings: plummeted 51.65% in 2022 and later decreased 14.21% in 2025.
- Year by year, Retained Earnings stood at -$19.5 million in 2021, then plummeted by 51.65% to -$29.6 million in 2022, then fell by 27.81% to -$37.9 million in 2023, then decreased by 14.93% to -$43.5 million in 2024, then decreased by 20.8% to -$52.6 million in 2025.
- Business Quant data shows Retained Earnings for TIVC at -$52.6 million in Q4 2025, -$49.6 million in Q3 2025, and -$47.0 million in Q2 2025.